Exact Sciences Corp. (NASDAQ: EXAS) filed a shelf registration statement for the sale of up to $150 million in equity, debt and warrants, according to the federal Securities and Exchange Commission.
In a press release, the Madison, Wisconsin-based molecular diagnostics developer said it does not have immediate plans to offer the securites, but wants to keep its options open.
Exact said use of proceeds from the sale of any securities will, at the time of any offering, be detailed in a supplement to the prospectus that the company filed for the shelf registration.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Exact Sciences’ net losses for its 2010 second quarter were almost double the company’s revenues, but still less than during the same period last year.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
